focus -WSS

focus

author：entertainment 2025-09-07 11:15:14 - browse：623

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

focus

WSS

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

Medical schools are missing the mark on artificial intelligence

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

FDA approves first new drug developed for postpartum depression

knowledge

focus

knowledge

Affirmative action in medical school literally saved lives

California Joshua trees severely burned in massive wildfire

In Memoriam: Notable people who died in 2023

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

Duchenne breakthrough therapy leaves behind pioneering families

Slain Parkland victim's father speaks out following reenactment

The high cost of giving birth even with insurance

Xenotransplantation trials will require adjusting expectations, experts say

FDA approval of Sarepta Duchenne genetic therapy gives me hope

'Cuddling' is just what the doctor ordered for a 200

focus

Does Medicare's free annual wellness visit do any good?

Climate activists disrupt London Pride march to protest corporate sponsorship

Patients, doctors are clashing about side effects of hormonal birth control

Eli Lilly’s Mounjaro succeeds in second weight

Medical schools are missing the mark on artificial intelligence

Can medical device makers keep up in the race to treat obesity?

focus

hotspot

focus

focus